Molecular imaging improves staging and treatment of pancreatic ductal adenocarcinomas
(Society of Nuclear Medicine and Molecular Imaging) For patients with pancreatic ductal adenocarcinomas (PDAC), molecular imaging can improve staging and clinical management of the disease, according to research published in the June issue of The Journal of Nuclear Medicine. In a retrospective study of PDAC patients, the addition of PET/CT imaging with 68Ga-FAPI led to restaging of disease in more than half of the patients, most notably in those with local recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Development of the world's first digital model of a cancer cell
(Graz University of Technology) The computer model, developed under the lead management of researchers at TU Graz, simulates the cyclical changes in the membrane potential of a cancer cell using the example of human lung adenocarcinoma and opens up completely new avenues in cancer research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
(Impact Journals LLC) All these preclinical data strongly suggest that the inhibition of mTORC1 and PLK1 proteins may be a promising therapeutic approach for NSCLC patients (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 30, 2021 Category: Biology Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Newly approved drug effective against lung cancer caused by genetic mutation
(Washington University School of Medicine) The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2021 Category: Cancer & Oncology Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pancreatic cancer: Mechanisms of metastasis
(Medical University of Vienna) A study led by MedUni Vienna sheds light on the mechanisms that lead to extremely aggressive metastasis in a particular type of pancreatic cancer, the basal subtype of ductal adenocarcinoma. The results contribute to a better understanding of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 5, 2021 Category: Drugs & Pharmacology Source Type: news

Increased use of minimally invasive non-endoscopic tests for Barrett's esophagus screening
(American College of Physicians) The authors of a new commentary from Mayo Clinic suggest that more extensive use of minimally invasive non-endoscopic tests for Barrett's esophagus (BE) screening could impact early detection and prevention of esophageal adenocarcinoma (EAC), a particularly deadly form of cancer. This is important because BE, the only known precursor to esophageal cancer, is often asymptomatic. Their commentary is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 3, 2021 Category: Infectious Diseases Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
TUESDAY, April 20, 2021 -- Opdivo (nivolumab) is now approved for the treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the U.S. Food and Drug Administration announced Friday. The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 20, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2021 Category: Drugs & Pharmacology Source Type: news

Pancreatic Cancer Surveillance in High-Risk: No Better Outcomes Pancreatic Cancer Surveillance in High-Risk: No Better Outcomes
Surveillance of people at high hereditary risk for pancreatic ductal adenocarcinoma can lead to diagnosis at an earlier stage, but as yet there is no clear survival benefit, a new study suggests.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 16, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma
Hematology / Oncology (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 16, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

What Is Lung Adenocarcinoma?
Title: What Is Lung Adenocarcinoma?Category: Diseases and ConditionsCreated: 4/16/2021 12:00:00 AMLast Editorial Review: 4/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 16, 2021 Category: Cancer & Oncology Source Type: news

AI System Beats Endoscopists for Detecting Neoplasia in Barrett's AI System Beats Endoscopists for Detecting Neoplasia in Barrett's
The deep-learning system is designed to reduce the rate of failed detection of high-grade dysplasia and early adenocarcinoma in patients undergoing surveillance by gastrointestinal endoscopists.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - April 2, 2021 Category: Internal Medicine Tags: Gastroenterology News Source Type: news

Variations in a gene and a protein aggravate the prognosis of one gastric tumor
(Universidad Complutense de Madrid) More than a million people worldwide were diagnosed with stomach cancer in 2018, the fifth most prevalent cancer. The most common gastric tumor is gastric adenocarcinoma, originating in the gastric mucosa. A research team led by the University Complutense of Madrid in Spain has identified 2 biomarkers that help predict the risk of developing the disease, as well as a poorer prognosis: polymorphisms-variations-of the transforming growth factor B1 (TGFB1) gene and the TGFB1 protein. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news

PET/MRI biomarkers guide personalized treatment for patients with pancreatic cancer
Positron emission tomography (PET)/MRI has changed how Mayo Clinic specialists treat patients with pancreatic cancer. Mayo Clinic pioneered the use of PET/MRI to manage pancreatic cancer. Now a new study by Ananya Panda, M.B.B.S., and colleagues systematically evaluates the strengths of PET/MRI for pancreatic ductal adenocarcinoma (PDAC). In less than five years, Mayo's PET/MRI practice [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 4, 2021 Category: Databases & Libraries Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Phase I/II Clinical Trial to Be Initiated in First Quarter 2021 CAMBRIDGE, Mass., Feb. 23, 2021 -- (Healthcare Sales & Marketing Network) -- Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on i... Biopharmaceuticals, Oncology, FDA Elicio Therapeutics, Amphiphile, KRAS, pancreatic ductal adenocarcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Is Adenocarcinoma of the Lung an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news

Is Intestinal Adenocarcinoma an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers probe new territory in treating patients with lung cancer during pandemic
(International Association for the Study of Lung Cancer) On February 27, 2020, the flagship journal of the International Association for the Study of Lung Cancer, the Journal of Thoracic Oncology, published a case study that described two patients from Wuhan, China who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

CRC Risk in Young Adults: Not as High as Previously Reported CRC Risk in Young Adults: Not as High as Previously Reported
Previous studies of colorectal cancer (CRC) included carcinoid tumors as well as colorectal adenocarcinoma, which has inflated estimates of risk, say experts.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 31, 2020 Category: Primary Care Tags: Hematology-Oncology News Source Type: news

Incidence of Young - Onset Esophageal Adenocarcinoma Rising
Young - onset esophageal adenocarcinoma presenting at more advanced stages; proportion of advanced stage up from 1975 to 2015 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 28, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Journal, Source Type: news

Incidence of Young-Onset Esophageal Adenocarcinoma Rising
MONDAY, Dec. 28, 2020 -- The incidence of young-onset esophageal adenocarcinoma is increasing, and patients present at more advanced stages compared with older patients, according to a study published online Dec. 11 in Cancer Epidemiology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2020 Category: Pharmaceuticals Source Type: news

CT radiomics predicts COVID-19 severity, outcome
A machine-learning algorithm based on CT radiomics can help clinicians predict...Read more on AuntMinnie.comRelated Reading: CT radiomics characterizes complex cystic renal lesions Radiomics enables prediction of invasive adenocarcinoma Imaging informatics: More than just AI at RSNA 2020 CT shows its value in the COVID-19 crisis Radiomics can aid management of lung cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 22, 2020 Category: Radiology Source Type: news

Early - Onset CRC Incidence Examined by Histologic Subtype
Adenocarcinomas increasing in most early - onset subgroups; carcinoid tumors increasing more steeply in all age groups (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Early-Onset CRC Incidence Examined by Histologic Subtype
MONDAY, Dec. 21, 2020 -- Among individuals with early-onset colorectal cancer (EOCRC), adenocarcinoma rates are increasing in specific subgroups, but carcinoid tumors are increasing more steeply in all age groups, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Incidence of esophageal adenocarcinoma is increasing in younger adults
(American Association for Cancer Research) Esophageal adenocarcinoma is occurring more frequently in adults under age 50, and these younger adults are more likely to be diagnosed at advanced stages. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news

Prostate Cancer Pathology Not Worse With Delayed Surgery
FRIDAY, Dec. 11, 2020 -- Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a higher risk for adverse pathological features or with worse overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2020 Category: Pharmaceuticals Source Type: news

PET/MRI, CT metrics assess pathologic response of pancreas cancer to neoadjuvant therapy
(American Roentgen Ray Society) According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), post-neoadjuvant therapy (NAT) changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma (PDA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Unexpected finding reveals new target for aggressive form of lung cancer
(Memorial Sloan Kettering Cancer Center) An MSK team has found that a particular subset of lung adenocarcinomas is aggressive due to a combination of two mutations that allow them to block ferroptosis, a type of cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2020 Category: Cancer & Oncology Source Type: news

What are Potential Problems Associated with Helicobacter pylori?
Discussion Helicobacter pylori (H. pylori) is a microaerophilis, spiral bacterium that is a prevalent human pathogen. How this infection affects individuals is different in adults and children. Overall seroprevalence rate in children world-wide was estimated to be ~33%, but this seroprevalence rate is decreasing in the developed world for both adults and children. It is acquired in childhood and can persist through colonization throughout life if untreated. Fortunately, it often is asymptomatic and generally does not cause serious disease in children. Some serotyping data shows that within families children acquire it more...
Source: PediatricEducation.org - November 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Radiomics enables prediction of invasive adenocarcinoma
A machine-learning algorithm based on radiomics features of pure ground-glass...Read more on AuntMinnie.comRelated Reading: CT shows COVID-19 causes lingering lung damage AI reduces missed lung cancers on chest x-ray Can radiomics improve CT lung cancer screening? Could CT lung screening benefit female never-smokers? ISCT: Will AI for CT be radiology's killer app? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 19, 2020 Category: Radiology Source Type: news

' Watch and Wait' Feasible for Some Rectal Cancer Patients
TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

PET/CT with Ga-68 tracer better for cancer patients
By attaching gallium-68 (Ga-68) to a fibroblast activation protein molecule...Read more on AuntMinnie.comRelated Reading: SNMMI: Multicancer radiotracer wins Image of the Year New class of radiotracers targets many cancer types Can radiomics detect pancreatic ductal adenocarcinoma? 2 new PET tracers may best FDG in cancer imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 2, 2020 Category: Radiology Source Type: news

Doubts About Stroma-Targeting Agents in Pancreatic Cancer Doubts About Stroma-Targeting Agents in Pancreatic Cancer
Adding pegvorhyaluronidase alfa to treatment with nab-paclitaxel and gemcitabine did not improve survival in adults with previously untreated metastatic pancreatic ductal adenocarcinoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Is Adenocarcinoma an Aggressive Cancer?
Title: Is Adenocarcinoma an Aggressive Cancer?Category: Diseases and ConditionsCreated: 7/30/2020 12:00:00 AMLast Editorial Review: 7/30/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2020 Category: Cancer & Oncology Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Prospective study shows increased risk for esophageal, gastric adenocarcinoma in two large cohorts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Oncology, ENT, Journal, Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
TUESDAY, July 21, 2020 -- Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma, according to a research letter published online July 20 in Gut. Chun-Han Lo, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2020 Category: Pharmaceuticals Source Type: news

Scientists reveal comprehensive proteomic map of human lung adenocarcinoma
(Chinese Academy of Sciences Headquarters) A team of Chinese scientists from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, National Center for Protein Sciences (Beijing), National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Shanghai Jiao Tong University, recently reported a comprehensive proteomic analysis based on 103 Chinese patients with lung adenocarcinoma (LUAD), a leading cause of death among all types of cancer worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

New guideline: Don't routinely screen for EAC in patients with chronic GERD
(Canadian Medical Association Journal) A new guideline from the Canadian Task Force on Preventive Health Care, based on a rigorous systematic review of the latest evidence, found no benefit of routine screening for esophageal adenocarcinoma (EAC) and precursor conditions (Barrett esophagus and dysplasia) in patients with chronic gastroesophageal reflux disease (GERD). The guideline, published in CMAJ (Canadian Medical Association Journal), recommends physicians in Canada continue current practice to not screen routinely http://www.cmaj.ca/lookup/doi/10.1503/cmaj.190814. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 6, 2020 Category: Cancer & Oncology Source Type: news